USP20 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL28569849	1.00	1/20
SCHEMBL28569850	1.00	1/20
SCHEMBL29448868	1.00	1/20
SCHEMBL29200274	0.68	1/20
SCHEMBL23885700	0.66	1/20
SCHEMBL23885095	0.55	1/20
SCHEMBL23885530	0.51	1/20
SCHEMBL23885618	0.51	1/20
SCHEMBL23885743	0.51	1/20
SCHEMBL28385395	0.51	1/20
SCHEMBL28385691	0.51	1/20
SCHEMBL30051948	0.51	1/20
SCHEMBL30053023	0.51	1/20
SCHEMBL23885223	0.50	1/20
SCHEMBL22692	0.49	1/20
SCHEMBL22693	0.49	1/20
SCHEMBL31350	0.49	1/20
SCHEMBL5858501	0.49	1/20
SCHEMBL979629	0.46	1/20
SCHEMBL19052373	0.46	1/20

Clinical trials — most relevant to USP20 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Multicenter Vitamin E Trial in Aging Persons With Down Syndrome	PHASE3	COMPLETED
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)	PHASE2	RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety	PHASE2	NOT_YET_RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
PCD New Gene Discovery	nan	COMPLETED
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a USP20 binder may also engage these)

Protein	Name	Similarity
Q8C6M1	—	1.000	Q8C6M1 →
Q5R5Z6	—	1.000	Q5R5Z6 →
A5PN09	—	1.000	A5PN09 →
A7Z056	—	1.000	A7Z056 →
B1WBD7	—	1.000	B1WBD7 →
A0JM59	—	0.999	A0JM59 →
A5PMR2	—	0.998	A5PMR2 →
A6QNM7	—	0.997	A6QNM7 →
Q8TEY7	—	0.994	Q8TEY7 →
Q8R5K2	—	0.993	Q8R5K2 →
Q28CN3	—	0.993	Q28CN3 →
Q5REG5	—	0.992	Q5REG5 →
Q8C2S0	—	0.992	Q8C2S0 →
Q8BW70	—	0.987	Q8BW70 →
Q3KR59	—	0.986	Q3KR59 →
Q5XGZ2	—	0.985	Q5XGZ2 →
D2HBJ8	—	0.984	D2HBJ8 →
Q7ZUM8	—	0.984	Q7ZUM8 →
Q8NB14	—	0.983	Q8NB14 →
B1AY15	—	0.982	B1AY15 →
Q5RED8	—	0.982	Q5RED8 →
O88974	—	0.982	O88974 →
P52479	—	0.982	P52479 →
USP10	Ubiquitin carboxyl-terminal hydrolase 10	0.981	landscape →
Q5RF77	—	0.981	Q5RF77 →
Q6NTR6	—	0.981	Q6NTR6 →
Q70CQ4	—	0.981	Q70CQ4 →
E7F6T8	—	0.981	E7F6T8 →
Q2NL57	—	0.981	Q2NL57 →
Q62925	—	0.980	Q62925 →